// App-Quantinova.ai

: Treatment response in COPD – does FEV1 say it all? An analysis of the CRYSTAL trial

Researchers

Presenter

  • Timm Greulich

Principal Investigators

  • Claus F. Vogelmeier

  • Alexander Mackay

  • Nadine Lossi

  • Maryam Aalamian-Mattheis

  • Xavier Nunez

  • Veronica Anna Pagano

  • Francesco Patalano

  • Andreas Clemens

  • Konstantinos Kostikas

Medical Centers

  • University Medical Center Giessen and Marburg, Member of the German Center for Lung Research (DZL), Marburg, Germany

  • National Heart and Lung Institute, Imperial College London, London, United Kingdom

  • Novartis Pharma GmbH, Nuernberg, Germany

  • Novartis AG, Basel, Switzerland

  • TFS Develop, Barcelona, Spain

Locations

  • Germany

  • United Kingdom

  • Switzerland

  • Spain

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • Catalase

Drug/Treatment

  • Seebri Breezhaler

  • indacaterol

Outcome

  • N/A

Study Design

  • Randomized

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved